The Acceptability, Safety, and Tolerability of Methadone/Naloxone in a 50: 1 Ratio

Experimental and Clinical Psychopharmacology

Volumn 17, Issue 3, 2009, Pages 146-153

  Bell, James ^a   Shearer, James ^a   Ryan, Anni ^a   Graham, Robert ^a   Korompay, Kristy ^a   Rizzo, Suzanne ^a   Sindhusake, Doungkamol ^b   Somogyi, Andrew A ^c  

^a The Langton Centre   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

diversion; methadone naloxone; pharmacodynamics; pharmacokinetics; precipitated withdrawal

Indexed keywords

BIODONE FORTE; DRUGS USED IN THE TREATMENT OF ADDICTION; METHADONE; METHADONE PLUS NALOXONE; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLD SWEAT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEROIN DEPENDENCE; HOT FLUSH; HUMAN; MALE; METHADONE TREATMENT; MULTICENTER STUDY; NAUSEA; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SLEEP DISORDER; URINALYSIS; WITHDRAWAL SYNDROME; YAWNING;

ADULT; AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HEROIN DEPENDENCE; HUMANS; INJECTIONS; MALE; METHADONE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 67650375937     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0016302     Document Type: Article

References (21)

1. Bell J., Shanahan M., Mutch C., Rea F., Ryan A., Batey R., et al. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 102 (2007) 1899-1907
2. Bloom, W., Sudderth, E., & Marcello, L. (1973). Clinical studies with naloxone/methadone in a ratio of 1:20. Paper presented at the Proceedings-Fifth National Conference on Methadone Treatment, March 17-19, 1973, Washington, DC, USA.
3. Caruso, F., Gordon, M., & Pachter, I. (1973). Methadone and Naloxone in Combination (NALDONE) for the Treatment of Heroin Addicts. Paper presented at the Proceedings-Fifth National Conference on Methadone Treatment, March 17-19, 1973, Washington, DC, USA.
4. Clarke S., Dargan P., and Jones A. Naloxone in opioid poisoning: Waking the tightrope. Emergency Medicine Journal 22 (2005) 612-616
5. Compton W., and Volkow N. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug and Alcohol Dependence 81 (2006) 103-107
6. Darke S., Topp L., and Ross J. The injection of methadone and benzodiazepines among Sydney injecting drug users 1996-2000: 5-year monitoring of trends from the Illicit Drug Reporting System. Drug & Alcohol Review 21 (2002) 27-32
7. Foster D., Somogyi A., White J., and Bochner F. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology 57 (2004) 742-755
8. Grabowski J., Rhoades H., Elk R., Schmitz J., and Creson D. Clinicwide and individualised behavioural interventions in drug dependence treatment. In: Onken L., Blaine J., and Boren J. (Eds). Behavioural treatments for drug abuse and dependence (1993), National Institute on Drug Abuse, Rockville, MD 37-71
9. Handelsman L., Cochrane K., Aronson M., Ness R., Rubinstein K., and Kanof P. Two new rating scales for opiate withdrawal. American Journal of Drug and Alcohol Abuse 13 (1987) 293-308
10. Humeniuk R., Ali R., McGregor C., and Darke S. Prevalence and correlates of Intravenous methadone syrup administration in Adelaide, Australia. Addiction 98 (2003) 413-418
11. Lintzeris N., Lenne M., and Ritter A. Methadone injecting in Australia: A tale of two cities. Addiction 94 (1999) 1175-1178
12. Loimer N., Presslich O., Grunberger J., and Linzmayer L. Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy. Journal of Substance Abuse Treatment 8 (1991) 157-160
13. Lugo R., Satterfield K., and Kern S. Pharmacokinetics of methadone. Journal of Pain & Palliative Care Pharmacotherapy 19 (2005) 13-24
14. Magnan J., Paterson S., Tavani A., and Kosterlitz H. The binding spectrum of naracotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmiedeberg's Archives of Pharmacology 319 (1982) 197-205
15. Mattick R., Breen C., Kimber J., and Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews (2003) CD002209
16. Neter J., Kutner M., Nachtsheim C., and Wasserman W. Applied linear statistical models. 4th ed. (1996), Irwin, Chicago
17. Nutt J.G., and Jasinski D.R. Methadone-naloxone mixtures for use in methadone maintenance programs. Clinical Pharmacology and Therapeutics 15 (1974) 156-166
18. Pani P., Pirastu R., Ricci A., and Gessa G. Prohibition of take-home dosages: Negative consequences on methadone maintenance treatment. Drug and Alcohol Dependence 41 (1996) 81-84
19. Parwatikar S.D., and Knowles R.R. Methadone-naloxone in combination for the treatment of heroin addicts. Clinical Pharmacology and Therapeutics 14 (1973) 941-948
20. Sunjic S., and Zador D. Methadone related deaths in New South Wales, July 1990 - December 1995. Drug and Alcohol Review 18 (1999) 409-416
21. Vlahov D., O'Driscoll P., Mehta S., Ompad D., Gern R., Galai N., et al. Risk factors for methadone outside treatment programs: Implications for HIV treatment among injection drug users. Addiction 102 (2007) 771-777